基于CRISPR的microRNA生物传感器用于癌症诊断
本文综述了基于CRISPR-Cas系统(尤其是Cas12a、Cas12b、Cas13a和Cas9)的循环microRNA生物传感器在癌症诊断中的最新进展,强调其分析性能与临床转化潜力,检测限通常在飞摩尔至阿摩尔范围。文章还比较了CRISPR工作流程与RT-qPCR和数字PCR,并提供了标准化、质量控制及临床验证标准的路线图。
要点
- CRISPR-Cas系统结合侧切核酸酶活性可实现多种信号放大与读出。
- 循环miRNA检测限通常达飞摩尔至阿摩尔范围。
- 临床转化需关注样本制备、抑制剂耐受、多重检测与定量读出。
核心结论
- CRISPR基miRNA生物传感器在癌症诊断中具有临床转化潜力,但需满足标准化与验证要求。
研究设计与样本
- 综述:评估基于CRISPR的miRNA生物传感器最新进展,涵盖血浆/血清、唾液、全血和细胞外囊泡样本。
主要发现
- CRISPR-Cas系统(Cas12a、Cas12b、Cas13a、Cas9)提供可编程核酸识别与高错配区分能力。
- 检测限通常为飞摩尔至阿摩尔范围。
- 临床转化受样本制备、抑制剂耐受、miRNA panel多重检测、定量读出和试剂稳定性等因素影响。
关键数值与推荐
- 检测限通常处于飞摩尔至阿摩尔范围。
- 文章提供了标准化和质量控制路线图以及临床化学实验室采用CRISPR技术所需的最低分析和临床验证标准。
临床怎么用
- 在临床化学实验室采用CRISPR技术时需参考标准化、质量控制及最低验证标准。
局限性
- 临床转化受样本制备、抑制剂耐受、多重检测、定量读出和试剂稳定性等因素影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Circulating microRNAs (miRNAs) are promising minimally invasive biomarkers for cancer and cardiovascular disorders. However, their low sequence length, low abundance, high sequence homology (including iso-miRs), and strong matrix and preanalytical effects in biofluids require highly sensitive and robust analytical technologies. CRISPR-Cas systems, particularly Cas12a, Cas12b, Cas13a, and Cas9, offer programmable nucleic acid recognition with high mismatch discrimination combined with collateral nuclease activity, enabling versatile signal amplification through fluorescence, electrochemical, electrochemiluminescent (ECL), photoelectrochemical (PEC), colorimetric, and lateral-flow readouts. This review critically evaluates the latest advances in CRISPR-based miRNA biosensors, emphasizing their analytical performance and translational potential in clinical diagnostics across plasma/serum, saliva, whole blood, and extracellular vesicle samples. The detection limits are typically within the femtomolar to attomolar range. The requirements for clinical translation are equally influenced by factors such as sample preparation, inhibitor tolerance, miRNA panel multiplexing, quantitative readout, and reagent stability. We compared CRISPR-based workflows with RT-qPCR and digital PCR and provided a roadmap for standardization and quality control, as well as the minimal analytical and clinical validation standards required for adopting CRISPR technology in clinical chemistry laboratories.
引用
- Habib AH, Sain ZM, Rafeeq M, et al. MicroRNA-CRISPR biosensors for cancer diagnostics. Clin Chim Acta. 2026. PMID: 41525963. doi:10.1016/j.cca.2026.120837
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。